[Evolocumab (Repatha®) : new evidence across the continuum of atherosclerotic cardiovascular disease].

Authors

Patrizio Lancellotti, André Scheen

Published in

Revue medicale de Liege. Volume 81. Issue 10. Pages 597-603.

Abstract

Evolocumab is a monoclonal antibody targeting PCSK9 that provides rapid and sustained LDL-cholesterol reduction. Following FOURIER, which demon-strated a reduction in cardiovascular events in patients with established atherosclerotic cardiovascular disease, VESALIUS-CV extends this benefit to high- or very-high-risk patients without previous myocardial infarction or stroke. These findings support earlier, intensive and sustained LDL-cholesterol lowering. This review summarizes the main evidence supporting evolocumab across the cardiovascular risk continuum.

PMID:
42861538
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.